240401-35-8 Usage
Uses
Used in Pharmaceutical Synthesis:
3-Azabicyclo[3.2.1]octan-8-one(9CI) is used as a building block in the synthesis of various pharmaceuticals and biologically active molecules. Its unique molecular structure allows for the creation of a wide range of compounds with potential therapeutic effects.
Used in Chemical Product Preparation:
3-Azabicyclo[3.2.1]octan-8-one(9CI) is employed in the preparation of diverse chemical products, such as insecticides, herbicides, and catalysts. Its versatile chemical properties make it a valuable component in the development of these products, enhancing their efficacy and performance.
Used in Organic Chemistry Research:
3-Azabicyclo[3.2.1]octan-8-one(9CI) is utilized in organic chemistry research to explore its unique molecular structure and chemical properties. This research contributes to the understanding of the compound's potential applications and the development of new synthetic methods and techniques.
Used in Medicinal Chemistry and Drug Development:
3-Azabicyclo[3.2.1]octan-8-one(9CI) is of great interest to researchers in medicinal chemistry and drug development due to its potential as a building block for the synthesis of new pharmaceuticals and biologically active molecules. Its unique structure and properties make it a promising candidate for the development of novel therapeutic agents.
Check Digit Verification of cas no
The CAS Registry Mumber 240401-35-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,4,0,4,0 and 1 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 240401-35:
(8*2)+(7*4)+(6*0)+(5*4)+(4*0)+(3*1)+(2*3)+(1*5)=78
78 % 10 = 8
So 240401-35-8 is a valid CAS Registry Number.
240401-35-8Relevant academic research and scientific papers
Scaffold hopping approach towards various AFQ-056 analogs as potent metabotropic glutamate receptor 5 negative allosteric modulators
Kubas, Holger,Meyer, Udo,Hechenberger, Mirko,Klein, Kai-Uwe,Plitt, Patrick,Zemribo, Ronalds,Spexgoor, Harm W.,Van Assema, Sander G.A.,Abel, Ulrich
supporting information, p. 6370 - 6376 (2013/11/19)
The metabotropic glutamate receptor subtype 5 has evolved into a promising target for the treatment of various diseases of the central nervous system, such as Fragile X and l-DOPA induced dyskinesia. One of the most advanced clinical compound is Novartis'
